- Home
- GH vs BSY Comparison
GH vs BSY Comparison
Compare GH & BSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | BSY |
|---|---|---|
| Founded | 2011 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 11.8B |
| IPO Year | 2018 | 2002 |
Fundamental Metrics
Financial Performance| Metric | GH | BSY |
|---|---|---|
| Price | $85.12 | $37.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 12 |
| Target Price | ★ $117.80 | $49.08 |
| AVG Volume (30 Days) | 1.7M | ★ 2.7M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | 6.74 | ★ 18.06 |
| EPS | N/A | ★ 0.85 |
| Revenue | ★ $982,021,000.00 | $734,849,000.00 |
| Revenue This Year | $33.40 | $13.47 |
| Revenue Next Year | $28.55 | $10.39 |
| P/E Ratio | ★ N/A | $44.59 |
| Revenue Growth | ★ 32.88 | 6.24 |
| 52 Week Low | $36.36 | $30.97 |
| 52 Week High | $120.74 | $59.25 |
Technical Indicators
Market Signals| Indicator | GH | BSY |
|---|---|---|
| Relative Strength Index (RSI) | 34.90 | 52.74 |
| Support Level | $82.26 | $37.70 |
| Resistance Level | $103.16 | $40.25 |
| Average True Range (ATR) | 3.94 | 1.01 |
| MACD | 0.07 | -0.09 |
| Stochastic Oscillator | 20.02 | 21.79 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About BSY Bentley Systems Incorporated Class B
Bentley Systems is a software vendor that caters to civil engineers, constructors, and geospatial professionals by enabling design, simulation, and data management of infrastructure assets such as roads and bridges. While Bentley is smaller than many other design software companies, it is a market leader across a handful of specialty areas, including public works, electricity grids, and transit.